Aclaris Therapeutics ACRS Single Reportable — Nonoperating Income Expense

Similar metrics at other companies

POWISingle Reportable — Nonoperating Income Expense

$2.47M-22.1%

ALMSSingle Reportable — Nonoperating Income Expense

$5.36M+109%

CAPRSingle Reportable — Nonoperating Income Expense

$2.83M+379%

TBPHSingle Reportable — Other Nonoperating Income Expense

$3.01M+221%

MMSISingle Reportable — Nonoperating Income Expense

$9.39M+405%

CLNESingle Reportable — Other Nonoperating Income Expense

$343K+4,188%

Questions, answered.

What is Aclaris Therapeutics's single reportable — nonoperating income expense?

Aclaris Therapeutics (ACRS) reported single reportable — nonoperating income expense of $2.37M in Q1 2026.

How has Aclaris Therapeutics's single reportable — nonoperating income expense changed year-over-year?

Aclaris Therapeutics's single reportable — nonoperating income expense decreased by 21.0% year-over-year, from $3M to $2.37M.

What does single reportable — nonoperating income expense mean?

This metric represents the net financial impact of activities outside the primary business operations of the segment, such as interest income, interest expense, or gains and losses from investments. It provides insight into the segment's financial health independent of its core research and development or service delivery activities. Monitoring this helps investors distinguish between operational performance and secondary financial results.